Evidence map›Paper›PMID 31325132›Full record

ArticleInternational urology and nephrology2019

Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer.

Keina Nozaki, Taketo Kawai, Tetsuya Fujimura, Hotaka Matsui, Taro Teshima, Takahiro Oshina, Atsuko Takahashi, Yusuke Sato, Daisuke Yamada, Takeshi Azuma and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Keina NozakiDepartment of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan. taketokawai@yahoo.co.jp.ORCID http://orcid.org/0000-0002-7279-2874
Tetsuya FujimuraDepartment of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Hotaka MatsuiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Taro TeshimaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Takahiro OshinaDepartment of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Atsuko TakahashiDepartment of Urology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Yusuke SatoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
Takeshi AzumaDepartment of Urology, Tokyo Metropolitan Tama Medical Center, 2-8-29, Musashidai, Fuchu-shi, Tokyo, 1838524, Japan.
Masatoshi HottaDepartment of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Kazuhiko NakajimaDepartment of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Hidetsugu NakayamaDepartment of Radiation Oncology, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Ryogo MinamimotoDepartment of Radiology, Division of Nuclear Medicine, Center Hospital of National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 1628655, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 1138655, Japan.
National Center for Global Health and Medicine · JPThe University of Tokyo · JPJichi Medical University · JPTokyo Metropolitan Tama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCarbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake.

methodsWe collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS).

resultsSeven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23-100%). Median PFS was 8.5 months (range, 2.8-25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases.

conclusions11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.

Indexed as

Carbon RadioisotopesPalliative CareAgedAged, 80 and overCholineHumansLongitudinal StudiesMalePositron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantRadiopharmaceuticalsCarbon RadioisotopesCholineRadiopharmaceuticals11-Choline positron emission tomography/computed tomographyCastration-resistant prostate cancerLocal therapyLymphadenectomyOligometastasisRadiotherapy

Identifiers

PMID31325132
OpenAlexW2963006571

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.